By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators discuss new findings in Ultrasound. According to news reporting originating from Vantaa, Finland, by NewsRx correspondents, research stated, "To characterise the feasibility and safety of a novel transurethral ultrasound (US)-therapy device combined with real-time multi-plane magnetic resonance imaging (MRI)-based temperature monitoring and temperature feedback control, to enable spatiotemporally precise regional ablation of simulated prostate gland lesions in a preclinical canine model. To correlate ablation volumes measured with intra-procedural cumulative thermal damage estimates, post-procedural MRI, and histopathology."
Our news editors obtained a quote from the research from Philips, "Three dogs were treated with three targeted ablations each, using a prototype MRI-guided transurethral US-therapy system (Philips Healthcare, Vantaa, Finland). MRI provided images for treatment planning, guidance, real-time multi-planar thermometry, as well as post-treatment evaluation of efficacy. After treatment, specimens underwent histopathological analysis to determine the extent of necrosis and cell viability. Statistical analyses (Pearson's correlation, Student's t-test) were used to evaluate the correlation between ablation volumes measured with intra-procedural cumulative thermal damage estimates, post-procedural MRI, and histopathology. MRI combined with a transurethral US-therapy device enabled multi-planar temperature monitoring at the target as well as in surrounding tissues, allowing for safe, targeted, and controlled ablations of prescribed lesions. Ablated volumes measured by cumulative thermal dose positively correlated with volumes determined by histopathological analysis (r(2) 0.83, P< 0.001). Post-procedural contrast-enhanced and diffusion-weighted MRI showed a positive correlation with non-viable areas on histopathological analysis (r(2) 0.89, P< 0.001, and r(2) 0.91, P = 0.003, respectively). Additionally, there was a positive correlation between ablated volumes according to cumulative thermal dose and volumes identified on post-procedural contrast-enhanced MRI (r(2) 0.77, P< 0.01). There was no difference in mean ablation volumes assessed with the various analysis methods (P > 0.05, Student's t-test). MRI-guided transurethral US therapy enabled safe and targeted ablations of prescribed lesions in a preclinical canine prostate model. Ablation volumes were reliably predicted by intra- and post-procedural imaging."
According to the news editors, the research concluded: "Clinical studies are needed to confirm the feasibility, safety, oncological control, and functional outcomes of this therapy in patients in whom focal therapy is indicated."
For more information on this research see: Magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy of the prostate: a preclinical study with radiological and pathological correlation using customised MRI-based moulds. BJU International, 2013;112(4):508-516. BJU International can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; BJU International - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1464-410X)
The news editors report that additional information may be obtained by contacting A. Partanen, Philips Healthcare, Vantaa, Finland. Additional authors for this research include N.K. Yerram, H. Trivedi, M.R. Dreher, J. Oila, A.N. Hoang, D. Volkin, J. Nix, B. Turkbey, M. Bernardo, D.C. Haines, C.J. Benjamin, W.M. Linehan, P. Choyke, B.J. Wood, G.J. Ehnholm, A.M. Venkatesan and P.A. Pinto (see also Ultrasound).
Keywords for this news article include: Vantaa, Europe, Finland, Therapy, Treatment, Ultrasound
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC